Metabolic dysfunction-associated steatotic liver disease (MASLD; formerly non-alcoholic fatty liver disease, NAFLD) is a common chronic liver disease strongly linked to obesity, metabolic syndrome (MetS), and type 2 diabetes. It starts as benign hepatic steatosis, but may progress to severe fibrosis, cirrhosis, or hepatocellular carcinoma. Today, MASLD represents one of the leading indications for liver transplantation. This review summarizes current knowledge on MASLD, including its pathogenesis, management strategies, regional disparities, and its specific relevance to women's health. The influence of sex hormones on MASLD has been documented. Polycystic ovary syndrome (PCOS) and the menopause increase MASLD prevalence by more than twofold. Moreover, PCOS increases the risk and severity of MASLD, independent of BMI. The role of menopausal hormone replacement therapy in MASLD remains controversial. However, transdermal estrogen and micronized progesterone or dydrogesterone seem to be more appropriate options. In pregnancy, MASLD is associated with >3-fold increased risk of gestational diabetes and preeclampsia. It may also increase the risk of MASLD development in the offspring-an effect that appears to be mitigated by breastfeeding for longer than six months. Given these findings, it is essential that clinicians involved in women's healthcare are aware of MASLD and its implications across the female lifespan.

Understanding MASLD: a growing women’s health concernMetabolic dysfunction-associated steatotic liver disease (MASLD), previously known as non-alcoholic fatty liver disease (NAFLD), is one of the most common chronic liver conditions today. It is closely linked to obesity, type 2 diabetes, and MetS. MASLD often begins as a simple fat buildup in the liver (steatosis), but over time, it can lead to serious complications such as liver scarring (fibrosis), cirrhosis, or even liver cancer. In fact, MASLD is now a leading reason for liver transplantation. This disease affects both men and women, but recent research highlights its impact on women’s health. Female sex hormones appear to influence MASLD risk. Conditions like PCOS and menopause significantly increase a woman’s likelihood of developing MASLD. Notably, women with PCOS are at higher risk of developing more severe liver disease, even if they are not overweight. The effect of the use of hormone replacement therapy (HRT) on MASLD is not clear. However, certain forms of HRT, like estrogen patches and progesterone that is chemically identical to the natural one, seem to be safer options for women with this condition who are considering HRT. MASLD can also pose some risks during pregnancy. It increases the risk for gestational diabetes and preeclampsia. Additionally, the presence of MASLD during a pregnancy might increase the child’s own risk of developing liver disease later in life. Fortunately, breastfeeding for more than six months may help reduce this risk. There is fast-growing and promising research in the field of MASLD management with medications. However, the most effective interventions still relate to lifestyle change, exercise and a healthy diet. In conclusion, MASLD has wide-reaching effects throughout a woman’s life, therefore, health providers who care for women should be aware of this condition and how to manage it effectively.

Biomedical Center Faculty of Medicine in Pilsen Charles University Pilsen Czech Republic

Department of Gynecology and Obstetrics; Faculty of Medicine in Pilsen Charles University Pilsen Czech Republic

Department of Histology and Embryology Faculty of Medicine in Pilsen Charles University Pilsen Czech Republic

Zobrazit více v PubMed

Rinella ME, Lazarus J V., Ratziu V, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Hepatology 2023; 78: 1966–1986. PubMed PMC

Estes C, Anstee QM, Arias-Loste MT, et al. Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016–2030. J Hepatol 2018; 69: 896–904. PubMed

Younossi ZM, Golabi P, Paik JM, et al. The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review. Hepatology 2023; 77: 1335–1347. PubMed PMC

Henry L, Paik J, Younossi ZM. Review article: the epidemiologic burden of non-alcoholic fatty liver disease across the world. Aliment Pharmacol Ther 2022; 56: 942–956. PubMed

Tacke F, Horn P, Wai-Sun Wong V, et al. EASL–EASD–EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). J Hepatol 2024; 81: 492–542. PubMed

Rinella ME, Neuschwander-Tetri BA, Siddiqui MS, et al. AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology 2023; 77: 1797–1835. PubMed PMC

Taylor RS, Taylor RJ, Bayliss S, et al. Association between fibrosis stage and outcomes of patients with nonalcoholic fatty liver disease: a systematic review and meta-analysis. Gastroenterology 2020; 158: 1611–1625.e12. PubMed

Ng CH, Lim WH, Hui Lim GE, et al. Mortality outcomes by fibrosis stage in nonalcoholic fatty liver disease: a systematic review and meta-analysis. Clin Gastroenterol Hepatol 2023; 21: 931–939.e5. PubMed PMC

Calzadilla-Bertot L, Jeffrey GP, Jacques B, et al. Increasing incidence of nonalcoholic steatohepatitis as an indication for liver transplantation in Australia and New Zealand. Liver Transpl 2019; 25: 25–34. PubMed

Younossi ZM, Stepanova M, Ong J, et al. Nonalcoholic steatohepatitis is the most rapidly increasing indication for liver transplantation in the United States. Clin Gastroenterol Hepatol 2021; 19: 580–589.e5. PubMed

Buzzetti E, Pinzani M, Tsochatzis EA. The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD). Metabolism 2016; 65: 1038–1048. PubMed

Donnelly KL, Smith CI, Schwarzenberg SJ, et al. Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J Clin Invest 2005; 115: 1343–1351. PubMed PMC

Lambert JE, Ramos–Roman MA, Browning JD, et al. Increased de novo lipogenesis is a distinct characteristic of individuals with nonalcoholic fatty liver disease. Gastroenterology 2014; 146: 726–735. PubMed PMC

Hassani Zadeh S, Mansoori A, Hosseinzadeh M. Relationship between dietary patterns and non-alcoholic fatty liver disease: a systematic review and meta-analysis. J Gastroenterol Hepatol 2021; 36: 1470–1478. PubMed

Ullah R, Rauf N, Nabi G, et al. Role of nutrition in the pathogenesis and prevention of non-alcoholic fatty liver disease: recent updates. Int J Biol Sci 2019; 15: 265–276. PubMed PMC

van der Windt DJ, Sud V, Zhang H, et al. The effects of physical exercise on fatty liver disease. Gene Expr 2018; 18: 89–101. PubMed PMC

Pälve KS, Pahkala K, Suomela E, et al. Cardiorespiratory fitness and risk of fatty liver: The Young Finns Study. Med Sci Sports Exerc 2017; 49: 1834–1841. PubMed

Qiu S, Cai X, Sun Z, et al. Association between physical activity and risk of nonalcoholic fatty liver disease: a meta-analysis. Therap Adv Gastroenterol 2017; 10: 701–713. PubMed PMC

Kim D, Vazquez-Montesino LM, Li AA, et al. Inadequate physical activity and sedentary behavior are independent predictors of nonalcoholic fatty liver disease. Hepatology 2020; 72: 1556–1568. PubMed

Yki-Järvinen H. Non-alcoholic fatty liver disease as a cause and a consequence of metabolic syndrome. Lancet Diabetes Endocrinol 2014; 2: 901–910. PubMed

Lonardo A, Nascimbeni F, Mantovani A, et al. Hypertension, diabetes, atherosclerosis and NASH: cause or consequence? J Hepatol 2018; 68: 335–352. PubMed

Lonardo A, Mantovani A, Lugari S, et al. NAFLD in some common endocrine diseases: prevalence, pathophysiology, and principles of diagnosis and management. Int J Mol Sci 2019; 20: 2841. PubMed PMC

Eslam M, Valenti L, Romeo S. Genetics and epigenetics of NAFLD and NASH: clinical impact. J Hepatol 2018; 68: 268–279. PubMed

Sookoian S, Pirola CJ. Meta-analysis of the influence of I148M variant of patatin-like phospholipase domain containing 3 gene (PNPLA3) on the susceptibility and histological severity of nonalcoholic fatty liver disease. Hepatology 2011; 53: 1883–1894. PubMed

Paik JM, Henry L, Younossi Y, et al. The burden of nonalcoholic fatty liver disease (NAFLD) is rapidly growing in every region of the world from 1990 to 2019. Hepatol Commun 2023; 7: e0251. PubMed PMC

Yip TC, Vilar-Gomez E, Petta S, et al. Geographical similarity and differences in the burden and genetic predisposition of NAFLD. Hepatology 2023; 77: 1404–1427. PubMed

Miller KC, Geyer B, Alexopoulos A-S, et al. Disparities in metabolic dysfunction-associated steatotic liver disease prevalence, diagnosis, treatment, and outcomes: a narrative review. Dig Dis Sci 2025; 70: 154–167. PubMed

Rieman-Klingler MC, Jung J, Tesfai K, et al. Integrating genetic and socioeconomic data to predict the progression of nonalcoholic fatty liver disease. Am J Biol Anthropol 2024; 184: e24979. PubMed PMC

Golovaty I, Tien PC, Price JC, et al. Food insecurity may be an independent risk factor associated with nonalcoholic fatty liver disease among low-income adults in the United States. J Nutr 2020; 150: 91–98. PubMed PMC

Kardashian A, Dodge JL, Terrault NA. Racial and ethnic differences in diet quality and food insecurity among adults with fatty liver and significant fibrosis: a U.S. population-based study. Aliment Pharmacol Ther 2022; 56: 1383–1393. PubMed PMC

Vilar-Gomez E, Nephew LD, Vuppalanchi R, et al. High-quality diet, physical activity, and college education are associated with low risk of NAFLD among the US population. Hepatology 2022; 75: 1491–1506. PubMed

Nasr P, Shang Y, Wester A, et al. Socioeconomic factors associated with the presence of and outcomes in metabolic dysfunction-associated steatotic liver disease. Liver Int 2024; 44: 3050–3059. PubMed

Koutny F, Aigner E, Datz C, et al. Relationships between education and non-alcoholic fatty liver disease. Eur J Intern Med 2023; 118: 98–107. PubMed

Cho J, Lee I, Park D-H, et al. Relationships between socioeconomic status, handgrip strength, and non-alcoholic fatty liver disease in middle-aged adults. Int J Environ Res Public Health 2021; 18: 1892. PubMed PMC

Azizi F, Hadaegh F, Hosseinpanah F, et al. Metabolic health in the Middle East and north Africa. Lancet Diabetes Endocrinol 2019; 7: 866–879. PubMed

Musso G, Cassader M, Paschetta E, et al. Bioactive lipid species and metabolic pathways in progression and resolution of nonalcoholic steatohepatitis. Gastroenterology 2018; 155: 282-302.e8. PubMed

Geng Y, Faber KN, de Meijer VE, et al. How does hepatic lipid accumulation lead to lipotoxicity in non-alcoholic fatty liver disease? Hepatol Int 2021; 15: 21–35. PubMed PMC

Caldwell S, Ikura Y, Dias D, et al. Hepatocellular ballooning in NASH. J Hepatol 2010; 53: 719–723. PubMed PMC

Rangwala F, Guy CD, Lu J, et al. Increased production of sonic hedgehog by ballooned hepatocytes. J Pathol 2011; 224: 401–410. PubMed PMC

Machado MV, Diehl AM. Hedgehog signalling in liver pathophysiology. J Hepatol 2018; 68: 550–562. PubMed PMC

Kazankov K, Jørgensen SMD, Thomsen KL, et al. The role of macrophages in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Nat Rev Gastroenterol Hepatol 2019; 16: 145–159. PubMed

Ibrahim SH, Hirsova P, Gores GJ. Non-alcoholic steatohepatitis pathogenesis: sublethal hepatocyte injury as a driver of liver inflammation. Gut 2018; 67: 963–972. PubMed PMC

Lefere S, Tacke F. Macrophages in obesity and non-alcoholic fatty liver disease: crosstalk with metabolism. JHEP Reports 2019; 1: 30–43. PubMed PMC

Chen VL, Morgan TR, Rotman Y, et al. Resmetirom therapy for metabolic dysfunction-associated steatotic liver disease: October 2024 updates to AASLD Practice Guidance. Hepatology 2025; 81: 312–320. PubMed

Koutoukidis DA, Koshiaris C, Henry JA, et al. The effect of the magnitude of weight loss on non-alcoholic fatty liver disease: a systematic review and meta-analysis. Metabolism 2021; 115: 154455. PubMed

Long MT, Noureddin M, Lim JK. AGA Clinical Practice Update: diagnosis and management of nonalcoholic fatty liver disease in lean individuals: expert review. Gastroenterology 2022; 163: 764–774.e1. PubMed PMC

Mantovani A, Petracca G, Beatrice G, et al. Non-alcoholic fatty liver disease and increased risk of incident extrahepatic cancers: a meta-analysis of observational cohort studies. Gut 2022; 71: 778–788. PubMed

Rocha ALL, Faria LC, Guimarães TCM, et al. Non-alcoholic fatty liver disease in women with polycystic ovary syndrome: systematic review and meta-analysis. J Endocrinol Invest 2017; 40: 1279–1288. PubMed

Shengir M, Chen T, Guadagno E, et al. Non-alcoholic fatty liver disease in premenopausal women with polycystic ovary syndrome: a systematic review and meta-analysis. JGH Open 2021; 5: 434–445. PubMed PMC

Wu J, Yao X-Y, Shi R-X, et al. A potential link between polycystic ovary syndrome and non-alcoholic fatty liver disease: an update meta-analysis. Reprod Health 2018; 15: 77. PubMed PMC

Petta S, Ciresi A, Bianco J, et al. Insulin resistance and hyperandrogenism drive steatosis and fibrosis risk in young females with PCOS. PLoS One 2017; 12: e0186136. PubMed PMC

Kim JJ, Kim D, Yim JY, et al. Polycystic ovary syndrome with hyperandrogenism as a risk factor for non-obese non-alcoholic fatty liver disease. Aliment Pharmacol Ther 2017; 45: 1403–1412. PubMed

Kumarendran B, O’Reilly MW, Manolopoulos KN, et al. Polycystic ovary syndrome, androgen excess, and the risk of nonalcoholic fatty liver disease in women: a longitudinal study based on a United Kingdom primary care database. PLoS Med 2018; 15: e1002542. PubMed PMC

Salva-Pastor N, López-Sánchez GN, Chávez-Tapia NC, et al. Polycystic ovary syndrome with feasible equivalence to overweight as a risk factor for non-alcoholic fatty liver disease development and severity in Mexican population. Ann Hepatol 2020; 19: 251–257. PubMed

Salva-Pastor N, Chávez-Tapia NC, Uribe M, et al. Understanding the association of polycystic ovary syndrome and non-alcoholic fatty liver disease. J Steroid Biochem Mol Biol 2019; 194: 105445. PubMed

Siwatch S, Singh V, Dhaliwal LK, et al. Non-alcoholic fatty liver disease in polycystic ovarian syndrome in Indian women. J Obstet Gynaecol (Lahore) 2022; 42: 957–961. PubMed

Sarkar M, Terrault N, Chan W, et al. Polycystic ovary syndrome (PCOS) is associated with NASH severity and advanced fibrosis. Liver International 2020; 40: 355–359. PubMed PMC

Nath J, Sharma S. Role of non-alcoholic fatty liver disease in cardiovascular morbidity in polycystic ovarian syndrome. J Assoc Physicians India 2022; 70: 11–12.

Sarkar M, Brady CW, Fleckenstein J, et al. Reproductive health and liver disease: Practice Guidance by the American Association for the Study of Liver Diseases. Hepatology 2021; 73: 318–365. PubMed

Rocha AL, Oliveira FR, Azevedo RC, et al. Recent advances in the understanding and management of polycystic ovary syndrome. F1000Res 2019; 8: 565. PubMed PMC

Said A, Akhter A. Meta-analysis of randomized controlled trials of pharmacologic agents in non-alcoholic steatohepatitis. Ann Hepatol 2017; 16: 538–547. PubMed

Frøssing S, Nylander M, Chabanova E, et al. Effect of liraglutide on ectopic fat in polycystic ovary syndrome: a randomized clinical trial. Diabetes Obes Metab 2018; 20: 215–218. PubMed

Mantovani A, Petracca G, Beatrice G, et al. Glucagon-like peptide-1 receptor agonists for treatment of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: an updated meta-analysis of randomized controlled trials. Metabolites 2021; 11: 73. PubMed PMC

Polyzos SA, Kountouras J, Mantzoros CS, et al. Effects of combined low-dose spironolactone plus vitamin E vs vitamin E monotherapy on insulin resistance, non-invasive indices of steatosis and fibrosis, and adipokine levels in non-alcoholic fatty liver disease: a randomized controlled trial. Diabetes Obes Metab 2017; 19: 1805–1809. PubMed

Liu S-H, Lazo M, Koteish A, et al. Oral contraceptive pill use is associated with reduced odds of nonalcoholic fatty liver disease in menstruating women: results from NHANES III. J Gastroenterol 2013; 48: 1151–1159. PubMed PMC

Yang JD, Abdelmalek MF, Guy CD, et al. Patient sex, reproductive status, and synthetic hormone use associate with histologic severity of nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol 2017; 15: 127–131.e2. PubMed PMC

Wang J, Wu AH, Stanczyk FZ, et al. Associations between reproductive and hormone-related factors and risk of nonalcoholic fatty liver disease in a multiethnic population. Clin Gastroenterol Hepatol 2021; 19: 1258–1266.e1. PubMed PMC

Azzaroli F, Mazzella G, Marchesini G, et al. Fatty liver in pregnancy: a narrative review of two distinct conditions. Expert Rev Gastroenterol Hepatol 2020; 14: 127–135. PubMed

Sarkar M, Grab J, Dodge JL, et al. Non-alcoholic fatty liver disease in pregnancy is associated with adverse maternal and perinatal outcomes. J Hepatol 2020; 73: 516–522. PubMed PMC

El Jamaly H, Eslick GD, Weltman M. Systematic review with meta-analysis: non-alcoholic fatty liver disease and the association with pregnancy outcomes. Clin Mol Hepatol 2022; 28: 52–66. PubMed PMC

Lee SM, Kwak SH, Koo JN, et al. Non-alcoholic fatty liver disease in the first trimester and subsequent development of gestational diabetes mellitus. Diabetologia 2019; 62: 238–248. PubMed

Lee SM, Kim BJ, Koo JN, et al. Nonalcoholic fatty liver disease is a risk factor for large-for-gestational-age birthweight. PLoS One 2019; 14: e0221400. PubMed PMC

Jung YM, Lee SM, Hong S, et al. The risk of pregnancy-associated hypertension in women with nonalcoholic fatty liver disease. Liver International 2020; 40: 2417–2426. PubMed

Lavrentaki A, Thomas T, Subramanian A, et al. Increased risk of non-alcoholic fatty liver disease in women with gestational diabetes mellitus: a population-based cohort study, systematic review and meta-analysis. J Diabetes Complications 2019; 33: 107401. PubMed

Hagström H, Höijer J, Ludvigsson JF, et al. Adverse outcomes of pregnancy in women with non-alcoholic fatty liver disease. Liver International 2016; 36: 268–274. PubMed

Qian Y, Zhang Y, Fan X, et al. Nonalcoholic fatty liver disease and adverse pregnancy outcomes in women with normal prepregnant weight. J Clin Endocrinol Metab 2023; 108: 463–471. PubMed

Wesolowski SR, Kasmi KC El, Jonscher KR, et al. Developmental origins of NAFLD: a womb with a clue. Nat Rev Gastroenterol Hepatol 2017; 14: 81–96. PubMed PMC

Patel S, Lawlor DA, Callaway M, et al. Association of maternal diabetes/glycosuria and pre-pregnancy body mass index with offspring indicators of non-alcoholic fatty liver disease. BMC Pediatr 2016; 16: 47. PubMed PMC

Ayonrinde OT, Oddy WH, Adams LA, et al. Infant nutrition and maternal obesity influence the risk of non-alcoholic fatty liver disease in adolescents. J Hepatol 2017; 67: 568–576. PubMed

Hagström H, Simon TG, Roelstraete B, et al. Maternal obesity increases the risk and severity of NAFLD in offspring. J Hepatol 2021; 75: 1042–1048. PubMed

Cantoral A, Montoya A, Luna-Villa L, et al. Overweight and obesity status from the prenatal period to adolescence and its association with non-alcoholic fatty liver disease in young adults: cohort study. BJOG 2020; 127: 1200–1209. PubMed

Cohen CC, Francis EC, Perng W, et al. Exposure to maternal fuels during pregnancy and offspring hepatic fat in early childhood: the healthy start study. Pediatr Obes 2022; 17: e12902. PubMed PMC

Williamson C, Nana M, Poon L, et al. EASL Clinical Practice Guidelines on the management of liver diseases in pregnancy. J Hepatol 2023; 79: 768–828. PubMed

Park Y, Sinn DH, Oh JH, et al. The association between breastfeeding and nonalcoholic fatty liver disease in parous women: a nation-wide cohort study. Hepatology 2021; 74: 2988–2997. PubMed

Ajmera VH, Terrault NA, VanWagner LB, et al. Longer lactation duration is associated with decreased prevalence of non-alcoholic fatty liver disease in women. J Hepatol 2019; 70: 126–132. PubMed PMC

Mantovani A, Beatrice G, Zusi C, et al. Breastfeeding duration and reduced risk of NAFLD in midlife of parous women. Explor Med 2021; 2: 378–381.

Nobili V, Bedogni G, Alisi A, et al. A protective effect of breastfeeding on the progression of non-alcoholic fatty liver disease. Arch Dis Child 2009; 94: 801–805. PubMed

Abeysekera KW, Orr JG, Madley-Dowd P, et al. Association of maternal pre-pregnancy BMI and breastfeeding with NAFLD in young adults: a parental negative control study. The Lancet Regional Health – Europe 2021; 10: 100206. PubMed PMC

Lonardo A, Suzuki A. Concise review: breastfeeding, lactation, and NAFLD. An updated view of cross-generational disease transmission and prevention. Metabolism and Target Organ Damage 2023; 3: 16.

Yuan Q, Wang H, Gao P, et al. Prevalence and risk factors of metabolic-associated fatty liver disease among 73,566 individuals in Beijing, China. Int J Environ Res Public Health 2022; 19: 2096. PubMed PMC

Jaroenlapnopparat A, Charoenngam N, Ponvilawan B, et al. Menopause is associated with increased prevalence of nonalcoholic fatty liver disease: a systematic review and meta-analysis. Menopause 2023; 30: 348–354. PubMed

Gutierrez-Grobe Y, Ponciano-Rodríguez G, Ramos MH, et al. Prevalence of non alcoholic fatty liver disease in premenopausal, posmenopausal and polycystic ovary syndrome women. The role of estrogens. Ann Hepatol 2010; 9: 402–409. PubMed

Balakrishnan M, Patel P, Dunn-Valadez S, et al. Women have a lower risk of nonalcoholic fatty liver disease but a higher risk of progression vs men: a systematic review and meta-analysis. Clin Gastroenterol Hepatol 2021; 19: 61–71.e15. PubMed PMC

Klair JS, Yang JD, Abdelmalek MF, et al. A longer duration of estrogen deficiency increases fibrosis risk among postmenopausal women with nonalcoholic fatty liver disease. Hepatology 2016; 64: 85–91. PubMed PMC

Wegermann K, Garrett ME, Zheng J, et al. Sex and menopause modify the effect of single nucleotide polymorphism genotypes on fibrosis in NAFLD. Hepatol Commun 2021; 5: 598–607. PubMed PMC

Palmisano BT, Zhu L, Stafford JM. Role of estrogens in the regulation of liver lipid metabolism. In: Dufour JF, Clavien PA, Trautwein C, Graf R, Chowdhury JR, eds. Advances in Experimental Medicine and Biology. New York, NY: Springer New York LLC, 2015, pp. 227–256. PubMed PMC

Lonardo A, Suzuki A. Sexual dimorphism of NAFLD in adults. Focus on clinical aspects and implications for practice and translational research. J Clin Med 2020; 9: 1278. PubMed PMC

du Plessis J, van Pelt J, Korf H, et al. Association of adipose tissue inflammation with histologic severity of nonalcoholic fatty liver disease. Gastroenterology 2015; 149: 635–48.e14. PubMed

Rakotoarivelo V, Lacraz G, Mayhue M, et al. Inflammatory cytokine profiles in visceral and subcutaneous adipose tissues of obese patients undergoing bariatric surgery reveal lack of correlation with obesity or diabetes. EBioMedicine 2018; 30: 237–47. PubMed PMC

Buskiewicz IA, Huber SA, Fairweather D. Sex hormone receptor expression in the immune system. In: Neigh GN, Mitzelfelt MS, eds. Sex Differences in Physiology. Amsterdam, Netherlands: Elsevier, pp. 45–60.

Bugianesi E, Pagotto U, Manini R, et al. Plasma adiponectin in nonalcoholic fatty liver is related to hepatic insulin resistance and hepatic fat content, not to liver disease severity. J Clin Endocrinol Metab 2005; 90: 3498–3504. PubMed

Ayonrinde OT, Olynyk JK, Beilin LJ, et al. Gender-specific differences in adipose distribution and adipocytokines influence adolescent nonalcoholic fatty liver disease. Hepatology 2011; 53: 800–809. PubMed

Polyzos SA, Kountouras J, Mantzoros CS. Adipokines in nonalcoholic fatty liver disease. Metabolism 2016; 65: 1062–1079. PubMed

Zhang H, Niu Y, Gu H, et al. Low serum adiponectin is a predictor of progressing to nonalcoholic fatty liver disease. J Clin Lab Anal 2019; 33: e22709. PubMed PMC

Shimizu I, Mizobuchi Y, Yasuda M, et al. Inhibitory effect of oestradiol on activation of rat hepatic stellate cells in vivo and in vitro. Gut 1999; 44: 127–136. PubMed PMC

Liu Q-H, Li D-G, Huang X, et al. Suppressive effects of 17beta-estradiol on hepatic fibrosis in CCl4-induced rat model. World J Gastroenterol 2004; 10: 1315–1320. PubMed PMC

Zhang B, Zhang C, Ji L, et al. Estrogen receptor β selective agonist ameliorates liver cirrhosis in rats by inhibiting the activation and proliferation of hepatic stellate cells. J Gastroenterol Hepatol 2018; 33: 747–55. PubMed

Cherubini A, Ostadreza M, Jamialahmadi O, et al. Interaction between estrogen receptor-α and PNPLA3 p. I148M variant drives fatty liver disease susceptibility in women. Nat Med 2023; 29: 2643. PubMed PMC

Zhang X, Mou Y, Aribas E, et al. Associations of sex steroids and sex hormone-binding globulin with non-alcoholic fatty liver disease: a population-based study and meta-analysis. Genes 2022; 13: 966. PubMed PMC

Park J-M, Lee HS, Oh J, et al. Serum testosterone level within normal range is positively associated with nonalcoholic fatty liver disease in premenopausal but not postmenopausal women. J Womens Health 2019; 28: 1077–1082. PubMed

Sarkar MA, Suzuki A, Abdelmalek MF, et al. Testosterone is associated with nonalcoholic steatohepatitis and fibrosis in premenopausal women with NAFLD. Clin Gastroenterol Hepatol 2021; 19: 1267–74.e1. PubMed PMC

Polyzos SA, Goulis DG. Menopause and metabolic dysfunction-associated steatotic liver disease. Maturitas 2024; 186: 108024. PubMed

Florentino GS, de A, Cotrim HP, Vilar CP, et al. Nonalcoholic fatty liver disease in menopausal women. Arq Gastroenterol 2013; 50: 180–5. PubMed

Hamaguchi M. Aging is a risk factor of nonalcoholic fatty liver disease in premenopausal women. World J Gastroenterol 2012; 18: 237. PubMed PMC

Miao M-Y, Han W-W, Lyu J-Q, et al. Female reproductive factors and metabolic dysfunction-associated steatotic liver disease: an integrated analysis of population cohort, liver imaging, and genetic data. Am J Obstet Gynecol. Epub ahead of print April 2025. DOI: 10.1016/j.ajog.2025.04.007. PubMed DOI

Kim SE, Min JS, Lee S, et al. Different effects of menopausal hormone therapy on non-alcoholic fatty liver disease based on the route of estrogen administration. Sci Rep 2023; 13: 15461. PubMed PMC

Eslam M, Fan J-G, Yu M-L, et al. The Asian Pacific association for the study of the liver clinical practice guidelines for the diagnosis and management of metabolic dysfunction-associated fatty liver disease. Hepatol Int 2025; 19: 261–301. PubMed